| 영문 | antacid | 한글 | 제산제 |
|---|---|---|---|
| 설명 | 위산은 아주 강력한 산이라서 보통의 조직은 모두 손상을 받을 수 밖에 없다. 하지만 위산의 영향을 직접받는 위의 점막은 특수한 메커니즘으로 인하여 위산으로 부터 보호를 받는다. 하지만 위산의 분비가 너무나 과도하던지 혹은 위점막의 보호를 하는 특수한 메커니즘이 약해지게 되면 위점막이 위산으로 인해서 손상을 받게 되다. 이렇게 위산과 위점막의 방어메커니즘이 평형을 이루지 못해서 위점막이 손상을 받는 것이 위궤양이다. 제산제란 위산을 중화할 수 있는 물질로써 위산의 산도를 나추며 위궤양의 치료에 쓰인다. |
||
| 영문 | oral administration | 한글 | 경구복용 |
|---|---|---|---|
| 설명 | 약을 투여하는 방법에는 여러 가지가 있다. 크게 나누어 보면, 입을 거쳐 위창자계를 통해 넣는 방법과 위창자계를 통하지 않고 바로 혈액으로 넣는 방법이 있다. 위창자계를 통하지 않는 방법으로 가장 흔한 방법은 주사를 이용하는 방법이다. 하지만, 이외에 항문을 통해 넣는 좌약식방법과 혀밑에 넣는 혀밑투여법도 있다. 그러나 대부분의 약제는 경구복용을 하게 된다. 경구복용에 대한 약자는 p.o.(per oral)로 표기한다. 경구복용제의 단점은 복용한 약제가 위창자관계를 거치면서 사람마다 각기 다른 흡수정도와 대사정도를 거치게 되므로 일정한 농도유지가 어렵다는데 있다. 또한 경구복용제의 모양이 캡슐형인지, 혹은 가루형인지에 따라서도 같은 약이지만, 서로 다른 효과를 나타낼 수 있다. |
||
| 영문 | oral cavity | 한글 | 구강 |
|---|---|---|---|
| 설명 | 입을 벌여서 입속에서 볼 수 있는 공간으로 입천장, 편도, 목젖을 볼 수 있다.  |
||
| 영문 | oral cavity | 한글 | 입안 |
|---|---|---|---|
| 설명 | 입을 벌여서 입속에서 볼 수 있는 공간으로 입천장, 편도, 목젖을 볼 수 있다. |
||
| FTOL | "Failed" Trial Of Labor; when a woman tries for a VBAC and ends up with a cesarean after a "trial of... |
|---|---|
| ORS | olfactory reference syndrome; oral rehydration solution; oral surgery, oral surgeon; Orthopaedic Res... |
| AAOC | antacid of choice |
| RCT | radiotherapy and chemotherapy; randomized clinical trial; randomized controlled trial; registered ca... |
| OCP | octacalcium phosphate; ocular cicatricial pemphigoid; oral case presentation; oral contraceptive pil... |
| BHAT | Beta-Blocker Heart Attack Trial |
|---|---|
| BCPT | Breast Cancer PRevention TRial |
| CAST | Cardiac Arrhythmia Suppression Trial |
| CARET | Carotene and Retinol Efficacy Trial |
| CATCH | Child and Adolescent Trial for Cardiovascular Health |
trial flask closure
triamterene
naso-oral
| antacid | <pharmacology> A substance that counteracts or neutralises acidity, usually of the stomach. Origin: L. Acidus = sour (16 Dec 1997) |
|---|---|
| Bernoulli trial | A single random event for which there are two and only two possible outcomes that are mutually exclusive and have a priori fixed (and complementary) probabilities of resulting. The trial is the realization of this process. Conventionally one outcome is termed a success and is assigned the score 1, the other is a failure and has the score zero. Thus the outcome might be 0 (no heads, one tail) or 1 (1 head, no tails). (05 Mar 2000) |
| randomised controlled trial | A clinical trial that involves at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Treatment allocations using coin flips, odd-even numbers, patient social security numbers, days of the week, medical record numbers, or other such pseudo- or quasi-random processes, are not truly randomised and a trial employing any of these techniques for patient assignment is designated simply a controlled clinical trial. (12 Dec 1998) |
| randomised trial | <statistics> A clinical trial in which patients have been randomly assigned to receive either the study drug or alternative treatment, in which neither the patient nor the physician conducting the study know which treatment is being given the patient, and in which the alternative to the study drug is a placebo, the study is conducted at several centres. (09 Oct 1997) |
| phase I clinical trial | <pharmacology> The earliest stage clinical trial for studying an experimental drug in humans. Phase I trials are generally comparatively small and are used to determine toxicity and maximum dose. They provide an initial evaluation of a drug's safety and pharmacokinetics-how the drug is absorbed, what tissues it reaches and how long it takes to leave the body. Such studies also usually test various doses of the drug (dose-ranging) to obtain an indication of the appropriate dose to use in later studies. The patients in these trials usually have advanced disease and have already received best available chemotherapy, therefore, seeing a repose is significant partially because this means there is a lack of cross-resistance between two anti-cancer drugs. (31 Dec 1997) |
| phase II clinical trial | <pharmacology> Usually focus on the activity of the new product as a single agent in a noncomparative, open study. (31 Dec 1997) |
| phase III clinical trial | <pharmacology> An advanced stage clinical trial that should conclusively show how well a drug works as compared to other treatments. Phase III trials are large, frequently multi-institution tests. They generally compare the relative value of the new drug compared with the current standard treatment and measure whether a new drug extends survival or otherwise improves the health of patients on treatment (clinical improvement) rather than just provide surrogate marker data. These studies generally last longer and are larger than phase II trials. (31 Dec 1997) |
| clinical trial | <pharmacology> Research study conducted with patients, usually to evaluate a new treatment or drug. Each trial is designed to answer scientific questions and to find better ways to treat individuals with a specific disease. (12 May 1997) |
| clinical trial, phase I | A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques based on a small number of healthy persons and conducted over the period of about a year in either the united states or a foreign country. (12 Dec 1998) |
| clinical trial, phase II | A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques based on several hundred volunteers, including a limited number of patients, and conducted over a period of about two years in either the united states or a foreign country. (12 Dec 1998) |
| clinical trial, phase III | A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques after phase II trials. A large enough group of patients is studied and closely monitored by physicians for adverse response to long-term exposure, over a period of about three years in either the united states or a foreign country. (12 Dec 1998) |
| clinical trial, phase IV | Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale after clinical trials, phases I, II, and III. These studies, conducted in the united states or a foreign country, often garner additional data about the safety and efficacy of a product. (12 Dec 1998) |
| controlled clinical trial | A clinical trial involving one or more test treatments, at least one control treatment, specified outcome measures for evaluating the studied intervention, and a bias-free method for assigning patients to the test treatment. The treatment may be drugs, devices, or procedures studied for diagnostic, therapeutic, or prophylactic effectiveness. Control measures include placebos, active medicine, no-treatment, dosage forms and regimens, historical comparisons, etc. When randomization using mathematical techniques, such as the use of a random numbers table, is employed to assign patients to test or control treatments, the trial is characterised as a randomised controlled trial. However, trials employing treatment allocation methods such as coin flips, odd-even numbers, patient social security numbers, days of the week, medical record numbers, or other such pseudo- or quasi-random processes are simply designated as controlled clinical trials. (12 Dec 1998) |
| controlled trial | A clinical study in which one group of participants receives an experimental drug while another group receives either a placebo or an approved standard therapy. When participants do not know which group they are in, the trial is blinded. See: Double-Blind. (09 Oct 1997) |
| prospective, randomised, double-blind clinical trial | <statistics> A clinical trial in which the method for analysing data has been specified in the protocol before the study has begun (prospective), the patients have been randomly assigned to receive either the study drug or alternative treatment, and in which neither the patient nor the physician conducting the study know which treatment is being given to the patient. (13 Nov 1997) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|